Case 1: RM is not an eligible patient for the nasal spray vaccine because she is older than 50 years. Moreover, because RM works in a hospital transplant unit, additional considerations apply.
The nasal spray vaccination is a live attenuated influenza vaccine approved for healthy patients aged 2 to 49 years who are not pregnant. According to the Centers for Disease Control and Prevention (CDC), people should not be vaccinated with the nasal spray if they are younger than 2 years or 50 years or older, have a chronic disease (particularly one that places them at high risk for complications from influenza, including chronic heart or lung disease, diabetes mellitus, or kidney failure), have a weakened immune system or are on immunosuppressants, are severely allergic to eggs, have a history ofGuillain-Barré syndrome, are younger than 5 years with a history of recurrent wheezing, or are children or adolescents receiving aspirin.
Although RM is not a candidate for the nasal vaccine because of her age, the pharmacist should also strongly consider RM’s job as a hospital transplant unit nurse in the decision-making process. As a health care professional who has frequent contact with immunocompromised patients, RM should not receive the nasal spray vaccine or should avoid contact with immunocompromised patients for 7 days after receiving it, per CDC recommendations. As this might interfere with her work schedule, the inactivated intramuscular or subvirion (intradermal) influenza injection is preferred
Case 2: The pharmacist should fill the prescription for oseltamivir, but not administer the nasal influenza vaccine (FluMist, MedImmune).
Anti-influenza (viral) prophylaxis is recommended for persons in households where one family member is at high risk of complications secondary to infection (ie, MC’s unvaccinated infant). However, anti-influenza antiviral drugs can inhibit replication of the live vaccine virus and may decrease the effectiveness of the live attenuated influenza vaccine nasal vaccine. For this reason, it is recommended that the patient wait at least 48 hours after the last dose of antiviral medication before receiving the nasal spray influenza vaccine. Alternatively, MC and other members of the household who have not yet been vaccinated can receive the inactivated influenza vaccine either intramuscularly or intradermally (Fluzone, Sanofi Pasteur; Fluvirin, Novartis) in conjunction with oseltamivir.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs